Drug Profile
Research programme: analgesics - CeNeS/Endo
Alternative Names: Analgesics research programme - CeNeS/EndoLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator CeNeS Pharmaceuticals; Endo Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 11 Sep 2002 Discontinued - Preclinical for Pain in USA (unspecified route)
- 31 Dec 2001 Endo has been merged with and into Endo Pharmaceuticals
- 16 Feb 2001 Cambridge NeuroScience is now called CeNeS Pharmaceuticals